Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk venous thrombosis

Thrombosis and Haemostasis

Volumn 91, Issue 4, 2004, Pages 712-718

  Legnani, Cristina ^a   Cini, Michela ^a   Cosmi, Benilde ^a   Mattarozzi, Silvia ^a   Lo Manto, Giuseppa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Activated protein C resistance; Deep vein thrombosis; Oral contraceptives; Risk factors

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; DESOGESTREL; GESTAGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DILUTION; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; PHLEBOGRAPHY; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; SENSITIVITY ANALYSIS; THROMBOPHILIA; ULTRASOUND; VENOUS THROMBOEMBOLISM;

EID: 1842637309     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-10-0621     Document Type: Article

References (31)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein-C - prediction of a cofactor to activated protein-C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
2. Bertina RM, Koeleman BPC, Koster T, et al.. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3. Aparicio C, Dahlbäck B. Molecular mechanisms of activated protein C resistance - properties of factor V isolated from an individual with homozygosity for the Arg(506) to Gln mutation in the factor V gene. Biochem J 1996; 313: 467-72.
4. Heeb MJ, Kojima Y, Greengard JS, et al.. Activated protein C resistance: Molecular mechanisms based on studies using purified Gln(506)-factor V. Blood 1995; 85: 3405-11.
5. Nicolaes GAF, Tans G, Thomassen MCLGD, et al.. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va(R506Q) by activated protein C. J Biol Chem 1995; 270: 21158-66.
6. Rosendaal FR, Koster T, Vandenbroucke JP, et al.. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
7. Ridker PM, Hennekens CH, Lindpainter K, et al.. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
8. Chan WP, Lee CK, Kwong YL, et al.. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135-9.
9. Williamson D, Brown K, Luddington R, et al.. Factor V Cambridge: A new mutation (Arg (306)→Thr) associated with resistance to activated protein C. Blood 1998; 91: 1140-4.
10. Bernardi F, Faioni EM, Castoldi E, et al.. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-7.
11. Zoller B, Svensson PJ, He XH, et al.. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
12. Cumming AM, Tait RC, Fildes S, et al.. Development of resistance to activated protein C during pregnancy. Br J Haematol 1995; 90: 725-7.
13. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, et al.. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen. Lancet 1995; 346: 1593-6.
14. Henkens CMA, Bom VJJ, Seinen AJ, et al.. Sensitivity to activated protein C: Influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
15. Jick H, Jick SS, Gurewich V, et al.. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
16. Olivieri O, Friso S, Manzato F, et al.. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
17. Spitzer WO, Lewis MA, Heinemann LAJ, et al.. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Br Med J 1996; 312: 83-8.
18. Rosing J, Middeldorp S, Curvers J, et al.. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study. Lancet 1999; 354: 2036-40.
19. Svensson PJ, Zoller B, Dahlbäck B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-5.
20. Ehrenforth S, Radtke KP, Scharrer I. Acquired activated protein C-resistance in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 797-8.
21. Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 7: 761-5.
22. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995; 74: 449-53.
23. de Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
24. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
25. Helmerhorst FM, Bloemenkamp KWM, Rosendaal FR, et al.. Oral contraceptives and thrombotic disease: Risk of venous thromboembolism. Thromb Haemost 1997; 78: 327-33.
26. Vandenbroucke JP, Koster T, Briet E, et al.. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
27. Aznar J, Vaya A, Estelles A, et al.. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000; 85: 1271-6.
28. Legnani C, Palareti G, Guazzaloca G, et al.. Venous thromboembolism in young women: Role of thrombophilic mutations and oral contraceptive use. Eur Heart J 2001; 23: 984-90.
29. Legnani C, Cosmi B, Valdrè L, et al.. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003; 1: 112-7.
30. Legnani C, Cosmi B, Cini M, et al.. High plasma levels of Factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol (submitted).
31. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.